INDEPENDENT NEWS

Munchkin US FDA Process on hold

Published: Thu 16 May 2019 01:52 PM
SYNLAIT MILK LIMITED ANNOUNCEMENT NZX: SML
ASX: SM1
16 May 2019
MUNCHKIN U.S. FDA PROCESS ON HOLD
The U.S. Food and Drug Administration (FDA) registration process required to launch Munchkin’s Grass Fed™ infant formula in the U.S. has been put on hold.
Synlait (NZX: SML; ASX: SM1) has been informed that the clinical study has been put on hold to allow Munchkin to explore other options in the U.S.
“Munchkin has not terminated its supply agreement with Synlait. For other markets where Grass Fed™ is sold the relationship continues with business as usual,” says Synlait CEO, Leon Clement.
The development will not have a material impact on Synlait’s forecast infant formula volumes.
ENDS

Next in Business, Science, and Tech

General Practices Begin Issuing Clause 14 Notices In Relation To The NZNO Primary Practice Pay Equity Claim
By: Genpro
Global Screen Industry Unites For Streaming Platform Regulation And Intellectual Property Protections
By: SPADA
View as: DESKTOP | MOBILE © Scoop Media